The global GLP-1 receptor agonist market, valued at over $50 billion in 2025, is entering a new phase. In Canada, patent and data exclusivity protections for semaglutide have expired, opening the door to generic competition. With nine manufacturers already filed for Health Canada approval, the first generic semaglutide products are expected as early as Q3 2026.
Canada's early entry stems from a lapsed administrative patent filing by Novo Nordisk, caused by the company's failure to pay renewal fees. Combined with the expiration of eight-year data exclusivity protections in January 2026, this created a clear regulatory pathway for generic entrants.
Sandoz CEO Richard Saynor has described Canada as a "testing ground" for semaglutide generic launches in other markets. Generic pricing in Canada is projected to fall to $100-$150 CAD per month, representing a potential 60-80% cost reduction.
Producing generic semaglutide at scale presents formidable technical challenges. Semaglutide is a complex 31-amino-acid peptide requiring sophisticated solid-phase peptide synthesis (SPPS), precise purification, and formulation into pre-filled injection pens.
Goldman Sachs projects that by 2030, global peptide API demand will reach approximately 99,000 kg. Peptide CDMOs like Bachem, PolyPeptide Group, CordenPharma, and AmbioPharm have invested heavily in GMP-scale peptide synthesis capacity. The peptide therapeutics CDMO market is projected to grow at approximately 13% annually through 2034.
Nine Canadian filings represent meaningful near-term capacity requirements before the larger U.S. market opens, projected for 2031-2033 when core semaglutide patents expire.
Bachem's Swiss facilities have been running at near-full utilization for GLP-1 API production. However, cold-chain logistics and stringent quality requirements mean that scaling production is neither fast nor cheap, making CDMO partnerships a critical competitive differentiator.
Goldman Sachs notes that China's manufacturing edge in synthetic peptide APIs could reshape competitive dynamics. Chinese suppliers offer 40-60% lower API pricing than Western CDMO equivalents. However, geopolitical tensions may limit reliance on Chinese API sources.
This creates a supply chain bifurcation: cost-sensitive emerging market launches may rely on Chinese API, while U.S. and European launches will favor qualified Western CDMOs. India's peptide manufacturing sector is positioned as a middle ground, offering cost-competitive API with Western-standard compliance.
The Canadian generic semaglutide launch is just the beginning. As additional markets including China, with over 17 generic candidates in Phase 3, move toward genericization, the global peptide API and CDMO industry faces a defining growth period.
Patent expiry is only the starting gun. The race to secure manufacturing capacity, establish reliable API supply chains, and navigate regulatory complexity will determine which players capture value in the post-patent GLP-1 era.
